Accera Launches Axona™, First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona™ in the United States for Alzheimer's disease (AD). Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's. Dispensed by prescription, it targets the metabolic deficiencies and imbalances associated with AD by providing an alternative energy source for brain cells. To view Multimedia News Release, go to http://www.prnewswire.com/mnr/axona/36444/

Icyou | March 2, 2009

Tags:. .Healthcare. .deficiencies. .mnr. .dispensed. .cns